WVU Cancer Institute Initiates First-In-Human Clinical Trial for Pancreatic Cancer
Post Summary
The West Virginia University (WVU) Cancer Institute is breaking new ground in the fight against pancreatic cancer with the launch of a first-in-human Phase I clinical trial. This global milestone focuses on a small implant that uses electric pulses to enhance the delivery of chemotherapy drugs directly to pancreatic tumors. The innovative approach aims to provide more targeted and effective treatment options for a cancer that remains one of the most challenging to manage, particularly in its advanced stages.
Pioneering Technology in Cancer Treatment
The trial, led by Brian Boone, M.D., an associate professor of surgical oncology in the WVU Department of Surgery, is testing a device that delivers gemcitabine, a commonly used chemotherapy agent, directly to the tumor. The groundbreaking method involves implanting a device laparoscopically into the pancreas. Through a process called iontophoresis, the device emits low-voltage electric pulses, diffusing the chemotherapy drug across a permeable membrane and directly into the pancreatic tissue.
"At the WVU Cancer Institute, our job is to take care of patients using cutting-edge technology and treatment that changes lives", said Brian Boone, M.D. "This trial provides patients who historically have had limited options, with access to new treatments that may be effective and less harmful while under the care of our Oncology Team. We are excited to be able to offer and evaluate these new therapies, which offer new hope for patients with pancreatic cancer."
sbb-itb-535baee
The Clinical Trial: Structure and Goals
Developed in collaboration with Continuity Biosciences, LLC, a clinical-stage biotechnology company, the trial represents a critical step in advancing treatment strategies for pancreatic cancer. Currently enrolling patients, the study includes two cohorts of 12 individuals diagnosed with non-metastatic, locally advanced, and unresectable pancreatic cancer. All participants will receive care under a nationally recognized oncology team.
The trial is being conducted at leading academic and cancer centers, including the WVU Cancer Institute and Michigan Medicine, the University of Michigan's academic medical center in Ann Arbor. If successful, this study could pave the way for more effective and less invasive treatments, significantly improving outcomes for pancreatic cancer patients.
A Step Toward Hope for a Challenging Disease
Pancreatic cancer continues to be one of the most difficult cancers to treat, especially in advanced stages. This trial offers a glimmer of hope to patients who have traditionally faced limited options, aiming to improve both the effectiveness of treatments and the quality of life for those battling the disease.
"This trial provides patients who historically have had limited options, with access to new treatments that may be effective and less harmful while under the care of our Oncology Team", said Dr. Boone. "We are excited to be able to offer and evaluate these new therapies, which offer new hope for patients with pancreatic cancer."
As the trial progresses, the WVU Cancer Institute is working to enroll eligible participants, advancing the potential for innovative therapies to transform pancreatic cancer care.
